BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma
- 15 October 2018
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (5) , 1283-1288
Abstract
Deletion polymorphism of BCL-2-like protein 11 (BIM) is specifically found in East Asia. To explain some epidemiological discrepancies between Asian and Western countries, we analyzed a silent single nucleotide polymorphism (SNP) in exon 5 (c465C > T) and a deletion site (2903 bp) in intron 2 in 77 patients with follicular lymphoma by the Q-invader method using PCR. In females, 5-year progression-free survivals (PFS) were 20.0% in the BIM deletion group, 66.7% in the SNP group and 81.5% in the wild-type (WT) group (p = .0012). In the WT group, 5-year PFS was 40.4% in males (p = .0448 vs. female PFS). This tendency was strengthened in patients receiving rituximab (26.9% vs. 84.2%, p = .006). Superior PFS in the WT females in Japan was comparable with the results of cohort studies in the United States and Sweden. Favorable prognosis in Japanese females may be masked by the BIM deletion polymorphism.Keywords
This publication has 23 references indexed in Scilit:
- The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancerCancer, 2014
- Analysis of BIM (BCL‐2 like 11 gene) deletion polymorphism in Chinese non‐small cell lung cancer patientsThoracic Cancer, 2014
- Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor MutationJournal of Thoracic Oncology, 2014
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC InhibitionCancer Research, 2013
- Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory studyAnnals of Oncology, 2013
- The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patientsBritish Journal of Haematology, 2012
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNature Medicine, 2012
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Bim–Bcl‐2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosisArthritis & Rheumatism, 2010
- Bim: a novel member of the Bcl‐2 family that promotes apoptosisThe EMBO Journal, 1998